EA202193155A1 - Селективные антагонисты h3-гистаминовых рецепторов для лечения расстройства аутистического спектра - Google Patents

Селективные антагонисты h3-гистаминовых рецепторов для лечения расстройства аутистического спектра

Info

Publication number
EA202193155A1
EA202193155A1 EA202193155A EA202193155A EA202193155A1 EA 202193155 A1 EA202193155 A1 EA 202193155A1 EA 202193155 A EA202193155 A EA 202193155A EA 202193155 A EA202193155 A EA 202193155A EA 202193155 A1 EA202193155 A1 EA 202193155A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
receptor antagonists
selective
autism spectrum
histamine receptor
Prior art date
Application number
EA202193155A
Other languages
English (en)
Russian (ru)
Inventor
Виктор Роман
Дьёрдь Иштван Леваи
Original Assignee
Рихтер Гедеон Нирт.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рихтер Гедеон Нирт. filed Critical Рихтер Гедеон Нирт.
Publication of EA202193155A1 publication Critical patent/EA202193155A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A61J3/071Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules
    • A61J3/074Filling capsules; Related operations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA202193155A 2019-05-31 2020-05-29 Селективные антагонисты h3-гистаминовых рецепторов для лечения расстройства аутистического спектра EA202193155A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP1900190A HU231525B1 (hu) 2019-05-31 2019-05-31 Szelektív hisztamin H3 receptor antagonisták autizmus spektrum betegség kezelésére
PCT/IB2020/055104 WO2020240489A1 (en) 2019-05-31 2020-05-29 Selective histamine h3 receptor antagonists for treating autism spectrum disorder

Publications (1)

Publication Number Publication Date
EA202193155A1 true EA202193155A1 (ru) 2022-03-22

Family

ID=89992916

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202193155A EA202193155A1 (ru) 2019-05-31 2020-05-29 Селективные антагонисты h3-гистаминовых рецепторов для лечения расстройства аутистического спектра

Country Status (8)

Country Link
US (1) US20220235034A1 (https=)
EP (1) EP3976035A1 (https=)
JP (1) JP2022534973A (https=)
CN (1) CN113905736A (https=)
CA (1) CA3141694A1 (https=)
EA (1) EA202193155A1 (https=)
HU (1) HU231525B1 (https=)
WO (1) WO2020240489A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE354568T1 (de) * 2000-08-08 2007-03-15 Ortho Mcneil Pharm Inc Nicht-imidazol aryloxypiperidine als h3 rezeptor liganden
HUP1300139A2 (en) * 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists

Also Published As

Publication number Publication date
HU231525B1 (hu) 2024-08-28
US20220235034A1 (en) 2022-07-28
CA3141694A1 (en) 2020-12-03
JP2022534973A (ja) 2022-08-04
WO2020240489A1 (en) 2020-12-03
CN113905736A (zh) 2022-01-07
EP3976035A1 (en) 2022-04-06
HUP1900190A1 (hu) 2020-12-28

Similar Documents

Publication Publication Date Title
MX2017003215A (es) Terapia de combinacion con cenicriviroc para el tratamiento de la fibrosis.
HK1258396A1 (zh) 用於治疗纤维化的赛尼克韦罗联合疗法
Karpel-Massler et al. Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide’s antiproliferative effect
CL2012002739A1 (es) Compuesto (r)-n-(3-(7-metil-1h-indazol-5-il)-1-(4-(1-metilpiperidin-4-il)piperazin-1-il)-1-oxopropan-2-il)-4-(2-oxo-1,2-dihidroquinolin-3-il)piperidina-1-carboxamida; composicion farmaceutica que lo comprende; uso del compuesto para el tratamiento de migraña, dolor neuropático, cancer de mama y glioma.
MX2020007898A (es) Moduladores de cinasa de proteina asociada con rho.
MX369576B (es) Imidazoles 2-piridilo sustituidos como inhibidores de alk5 y/o alk4.
MX2019003726A (es) Metodos para tratar fibroides uterinos y endometriosis.
UA112514C2 (uk) АНТАГОНІСТИ C5aR
MX386113B (es) Polimorfos de n-[(3-fluoro-4-metoxipiridin-2-il)metil]-3-(metoximetil)-1-({4-[(2-oxopiridin-1-il)metil]fenil}metil)pirazol-4-carboxamida y sales de los mismos.
PE20120626A1 (es) Composiciones farmaceuticas que comprende nilotinib
MX2015018032A (es) Análogos sustituidos de (e)-n'-(1-feniletiliden)benzohidrazida como inhibidores de histona desmetilasa.
MX2016004342A (es) Formulaciones de (s)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoi ndolin-2-il)piperidin-2,6-diona.
MX2017010348A (es) Compuestos de amida como agonistas del receptor de la 5-hidroxitriptamina 4 (5-ht4).
EA202192320A1 (ru) Кристаллическая форма моногидрата 1-(1-оксо-1,2-дигидроизохинолин-5-ил)-5-(трифторметил)-n-[2-(трифторметил)пиридин-4-ил]-1h-пиразол-4-карбоксамида
SA522441554B1 (ar) Ripk1 مركبات أيزوكسازوليدين كمثبطات واستخدامها
MX2020008375A (es) Compuestos de heteroarilo, composiciones farmaceuticas de los mismos y su uso terapeutico.
EA201890764A1 (ru) Селективные антагонисты nr2b
EA201692474A1 (ru) Производные 1-(циклопент-2-ен-1-ил)-3-(2-гидрокси-3-(арилсульфонил)фенил)мочевины в качестве ингибиторов cxcr2
CY1124056T1 (el) Κρυσταλλικες μορφες της μηλεϊνικης 1-((2r, 4r)-2-(1η-βενζο[d] iμιδαζολ-2-υλο)-1-μεθυλοπιπεριδιν-4-υλο)-3-(4-κυανοφαινυλ) ουριας
MX388589B (es) Nuevo uso terapeutico de h3-ligandos.
EA201992704A1 (ru) Новое применение агониста формил-пептидного рецептора 2/рецептора липоксина a4 (fpr2/alx) для лечения сердечной недостаточности
EA201691160A1 (ru) Антагонисты s1p3
EA202193155A1 (ru) Селективные антагонисты h3-гистаминовых рецепторов для лечения расстройства аутистического спектра
MX379454B (es) Derivados de fluoroindol como moduladores alostéricos positivos del receptor m1 muscarínico.
EA201892528A1 (ru) Трехкомпонентная комбинация чистых антагонистов 5-htрецепторов, ингибиторов ацетилхолинэстеразы и антагониста nmda рецептора